CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016
This article was originally published in The Pink Sheet Daily
Pharmacy benefit manager CVS is considering a range of drugs and indications for the program, noting some oncology approvals in the coming months may be eligible.
You may also be interested in...
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.